Document:

Exhibit
4.2

 

THE
REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT
EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR
HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING [●], 2021 (THE “EFFECTIVE DATE”)
TO ANYONE OTHER THAN (I) AEGIS CAPITAL CORP. OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING FOR WHICH THIS PURCHASE WARRANT WAS
ISSUED TO THE UNDERWRITER AS CONSIDERATION (THE “OFFERING”), OR (II) A BONA FIDE OFFICER OR PARTNER OF AEGIS
CAPITAL CORP.

 

THIS
PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [●], 2021. VOID AFTER 5:00 P.M., EASTERN TIME, [●], 2026.

 

Ordinary
Share Purchase Warrant

 

For
the Purchase of [●] Ordinary Shares

 

of

 

Maris-Tech
Ltd.

 

1. Purchase
Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”),
as registered owner of this Purchase Warrant, to Maris-Tech Ltd., an Israeli company (the “Company”), Holder
is entitled, at any time or from time to time beginning [●], 2021 (the “Commencement Date”), and at or
before 5:00 p.m., Eastern time, on [●], 2026 (the “Expiration Date”), but not thereafter, to
subscribe for, purchase and receive, in whole or in part, up to [●] ordinary shares of the Company, no par value per share (the
“Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is not a Business Day,
then this Purchase Warrant may be exercised on the next succeeding Business Day. During the period ending on the Expiration Date, the
Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[●]
per Share; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the
rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise,
shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the
adjusted exercise price, depending on the context, and the term “Business Day” shall mean a day other than a
Saturday, Sunday or any other day which is a federal legal holiday in the United States or any day on which the Federal Reserve Bank of
New York is authorized or required by law or other governmental action to close, provided that the Federal Reserve Bank of New York shall
not be deemed to be authorized or obligated to be closed due to a “shelter in place,” “non-essential employee”
or similar closure of physical location at the direction of any governmental authority if the bank’s electronic funds transfer systems
(including for wire transfers) are open for use by customers on such day.

 

2.
Exercise.

 

2.1
Exercise Form. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed
and delivered to the Company, together with this Purchase Warrant and, subject to Section 2.2, payment of the Exercise Price for the Shares being purchased payable
in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or official bank
check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration Date,
this Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and expire.
Each exercise hereof shall be irrevocable.

 

     

     

    

 

2.2
Cashless Exercise. In lieu of exercising this Purchase Warrant by payment of cash or check payable to the order of the Company
pursuant to Section 2.1 above, Holder may elect to receive the number of Shares equal to the value of this Purchase Warrant (or the portion
thereof being exercised), by surrender of this Purchase Warrant to the Company, together with the exercise form attached hereto, in which
event the Company will issue to Holder Shares in accordance with the following formula:

 

	X	=	Y(A-B)	 
	A	 
	Where,	 	 	 
	 	X	=	The number of Shares to be issued to Holder;
	 	Y	=	The number of Shares for which the Purchase
    Warrant is being exercised;
	 	A	=	The fair market value of one Share; and
	 	B	=	The Exercise Price.
	 	 	 	 	 	 	 

For
purposes of this Section 2.2, the fair market value of a Share is defined as follows:

 

(i)
if the Company’s ordinary shares are traded on a national securities exchange, the OTCQB or OTCQX, the fair market value shall
be deemed to be the closing price on such exchange, the OTCQB or OTCQX, as the case may be, on the Business Day immediately
preceding the date that the exercise form is delivered pursuant to Section 8.4 in connection with the exercise of the Purchase
Warrant; or

 

(ii)
if the Company’s ordinary shares are not then traded on a national securities exchange, the OTCQB or OTCQX and if prices for
the Company’s ordinary shares are then reported on the “Pink Sheets” published by OTC Markets Group, Inc., the
fair market value shall be deemed to be the closing bid prior to the exercise form being submitted in connection with the exercise
of the Purchase Warrant so reported; provided, however, if there is no active public market, the value shall be the fair market
value thereof, as determined in good faith by the Company’s Board of Directors. 

 

2.3
Legend. Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities
have been registered under the Securities Act of 1933, as amended (the “Act”):

 

The
securities represented by this certificate have not been registered under the Securities Act of 1933, as amended (the “Act”),
or applicable state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred except
pursuant to an effective registration statement under the Act, or pursuant to an exemption from registration under the Act and applicable
state law which, in the opinion of counsel to Maris-Tech Ltd., is available.

 

2.4
Resale of Shares. Holder and the Company acknowledge that as of the date hereof the Staff of the Division of Corporation Finance
of the SEC has published Compliance & Disclosure Interpretation 528.04 in the Securities Act Rules section thereof, stating that
the holder of securities issued in connection with a public offering may not rely upon Rule 144 promulgated under the Act to establish
an exemption from registration requirements under Section 4(a)(1) under the Act, but may nonetheless apply Rule 144 constructively for
the resale of such shares in the following manner: (a) provided that six months has elapsed since the last sale under the registration
statement, an underwriter or finder may resell the securities in accordance with the provisions of Rule 144(c), (e), and (f), except
for the notice requirement; (b) a purchaser of the shares from an underwriter receives restricted securities unless the sale is made
with an appropriate, current prospectus, or unless the sale is made pursuant to the conditions contained in (a) above; (c) a purchaser
of the shares from an underwriter who receives restricted securities may include the underwriter’s holding period, provided that
the underwriter or finder is not an affiliate of the issuer; and (d) if an underwriter transfers the shares to its employees, the employees
may tack the firm’s holding period for purposes of Rule 144(d), but they must aggregate sales of the distributed shares with those
of other employees, as well as those of the underwriter or finder, for a six-month period from the date of the transfer to the employees.
Holder and the Company also acknowledge that the Staff of the Division of Corporation Finance of the SEC has advised in various no-action
letters that the holding period associated with securities issued without registration to a service provider commences upon the completion
of the services, which the Company agrees and acknowledges shall be the final closing of the Offering, and that Rule 144(d)(3)(ii) provides
that securities acquired from the issuer solely in exchange for other securities of the same issuer shall be deemed to have been acquired
at the same time as the securities surrendered for conversion (which the Company agrees is the date of the initial issuance of this Purchase
Warrant). In the event that following a reasonably-timed written request by Holder to transfer the Shares in accordance with Compliance
& Disclosure Interpretation 528.04 counsel for the Company in good faith concludes that Compliance & Disclosure Interpretation
528.04 no longer may be relied upon as a result of changes in applicable laws, regulations, or interpretations of the SEC Division of
Corporation Finance, or as a result of judicial interpretations not known by the Company or its counsel on the date hereof (either, a
“Registration Trigger Event”), then the Company shall promptly, and in any event within five (5) Business Days
following the request, provide written notice to Holder of such determination. As a condition to giving such notice, the parties shall
negotiate in good faith a single demand registration right pursuant to an agreement in customary form reasonably acceptable to the parties;
provided that notwithstanding anything to the contrary, the obligations of the Company pursuant to this Section 2 shall terminate on
the fifth anniversary of the commencement of sales of the public offering. In the absence of such conclusion by counsel for the Company,
the Company shall, upon such a request of Holder given no earlier than six months after the final closing of the Offering, instruct its
transfer agent to permit the transfer of such shares in accordance with Compliance & Disclosure Interpretation 528.04, provided that
Holder has provided such documentation as shall be reasonably be requested by the Company to establish compliance with the conditions
of Compliance & Disclosure Interpretation 528.04. Notwithstanding anything to the contrary, pursuant to FINRA Rule 5110(g)(8)(A),
the Holder shall not be entitled to more than one demand registration right hereunder and the duration of the registration rights hereunder
shall not exceed five years from the commencement of sales of the public offering.

 

    2

     

    

 

3.
Transfer.

 

3.1
General Restrictions. The registered Holder of this Purchase Warrant agrees by such Holder’s acceptance hereof, that such Holder
will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant for a period of one hundred eighty (180) days following
the Effective Date to anyone other than: (i) Holder or an underwriter, placement agent,
or a selected dealer participating in the Offering, or (ii) a bona fide officer or partner of Holder or of any such underwriter, placement
agent or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(g)(1), or (b) for a period of one hundred eighty (180)
days following the Effective Date cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging,
short sale, derivative, put or call transaction that would result in the effective economic disposition of this Purchase Warrant or the
securities hereunder, except as provided for in FINRA Rule 5110(g)(2). After 180 days after the Effective Date, transfers to others may
be made subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder
must deliver to the Company the assignment form attached hereto duly executed and completed, together with the Purchase Warrant and payment
of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) Business Days transfer this Purchase
Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate
assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of such number
as shall be contemplated by any such assignment.

 

3.2
Restrictions Imposed by the Act. The securities evidenced by this Purchase Warrant shall not be transferred unless and until:
(i) if required by applicable law, the Company has received the opinion of counsel for the Company that the securities may be transferred
pursuant to an exemption from registration under the Act and applicable state securities laws, or (ii) a registration statement or a
post-effective amendment to the Registration Statement relating to the offer and sale of such securities has been filed by the Company
and declared effective by the U.S. Securities and Exchange Commission (the “Commission”) and compliance with
applicable state securities law has been established.

 

4.
Piggyback Registration Rights.

 

4.1
Grant of Right. In the event that there is not an effective registration statement
covering the Purchase Warrant or the underlying Shares, whenever the Company proposes to register any of its ordinary shares under the
Act (other than (i) a registration effected solely to implement an employee benefit plan or a transaction to which Rule 145 of the Act
is applicable, or (ii) a registration statement on Form S-4, S-8 or any successor form thereto or another form not available for registering
the Shares issuable upon exercise of this Purchase Warrant for sale to the public, whether for its own account or for the account of one
or more stockholders of the Company (a “Piggyback Registration”), the Company shall give prompt written notice
(in any event no later than ten (10) Business Days prior to the filing of such registration statement) to the Holder of the Company’s
intention to effect such a registration and, subject to the remaining provisions of this Section 4.1, shall include in such registration
such number of Shares underlying this Purchase Warrant (the “Registrable Securities”) that the Holders have
(within ten (10) Business Days of the respective Holder’s receipt of such notice) requested in writing (including such number) to
be included within such registration. If a Piggyback Registration is an underwritten offering and the managing underwriter advises the
Company that it has determined in good faith that marketing factors require a limit on the number of ordinary shares to be included in
such registration, including all Shares issuable upon exercise of this Purchase Warrant (if the Holder has elected to include such shares
in such Piggyback Registration) and all other ordinary shares proposed to be included in such underwritten offering, the Company shall
include in such registration (i) first, the number of ordinary shares that the Company proposes to issue and sell pursuant to such underwritten
offering and (ii) second, the number of ordinary shares, if any, requested to be included therein by selling stockholders (including the
Holder) allocated pro rata among all such persons on the basis of the number of ordinary shares then owned by each such person. If any
Piggyback Registration is initiated as a primary underwritten offering on behalf of the Company, the Company shall select the investment
banking firm or firms to act as the managing underwriter or underwriters in connection with such offering. Notwithstanding anything to
the contrary, the obligations of the Company pursuant to this Section 4.1 shall terminate on the earlier of (i) the fifth anniversary
of the Effective Date and (ii) the date that Rule 144 would allow the Holder to sell its Registrable Securities during any ninety (90)
day period, and shall not be applicable so long as the Company’s Registration Statement on Form F-1 (No. 333-[●] covering
the Registrable Securities remains effective at such time. The duration of the piggyback registration right shall not exceed seven years
from the commencement of sales of the public offering.

 

    3

     

    

 

4.2
Indemnification. The Company shall indemnify the Holder(s) of the Registrable Securities
to be sold pursuant to any registration statement hereunder and each person, if any, who controls such Holders within the meaning of Section
15 of the Act or Section 20 (a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), against
all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other out-of-pocket expenses reasonably
incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Act,
the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the provisions
pursuant to which the Company has agreed to indemnify Holder contained in the Underwriting Agreement between Holder and the Company, dated
as of [●], 2021. The Holder(s) of the Registrable Securities to be sold pursuant to such registration statement, and their successors
and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including
all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim
whatsoever) to which they may become subject under the Act, the Exchange Act or otherwise, arising from information furnished by or on
behalf of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration statement to the same
extent and with the same effect as the provisions contained in the Underwriting Agreement pursuant to which Holder has agreed to indemnify
the Company.

 

4.3
Exercise of Purchase Warrants. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise
their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

 

4.4
Documents Delivered to Holders. The Company shall deliver promptly to each Holder participating in the offering requesting the
correspondence and memoranda described below, copies of all correspondence between the Commission and the Company, its counsel or auditors
and all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each
Holder and underwriter to do such investigation, upon reasonable advance notice, with respect to information contained in or omitted
from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation
shall include access to books, records and properties and opportunities to discuss the business of the Company with its officers and
independent auditors, all to such reasonable extent and at such reasonable times, during normal business hours, as any such Holder shall
reasonably request.

 

4.5
Underwriting Agreement. The Holders shall be parties to any underwriting agreement relating to a Piggyback Registration. Such
Holders shall not be required to make any representations or warranties to or agreements with the Company or the underwriters except
as they may relate to such Holders, their Shares and the amount and nature of their ownership thereof and their intended methods of distribution.

 

4.6
Documents to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to
the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security
holders.

 

4.7
Damages. Should the Company fail to comply with such provisions, the Holder(s) shall, in addition to any other legal or other
relief available to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against
the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and
without the necessity of posting bond or other security.

 

5.
New Purchase Warrants to be Issued.

 

5.1
Partial Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned
in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation,
together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised
pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor
to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of Shares purchasable hereunder
as to which this Purchase Warrant has not been exercised or assigned.

 

    4

     

    

 

5.2
Lost Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of
this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, determined in the sole discretion of the
Company, the Company shall execute and deliver a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed
and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the
part of the Company.

 

6.
Adjustments.

 

6.1
Adjustments to Exercise Price and Number of Securities. The Exercise Price and the number of Shares underlying the Purchase Warrant
shall be subject to adjustment from time to time as hereinafter set forth:

 

6.1.1
Share Dividends; Split Ups. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of
outstanding Shares is increased by a stock dividend payable in Shares or by a split up of Shares or other similar event, then, on the
effective day thereof, the number of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding Shares,
and the Exercise Price shall be proportionately decreased.

 

6.1.2
Aggregation of Shares. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding
Shares is decreased by a consolidation, combination or reclassification of Shares or other similar event, then, on the effective date
thereof, the number of Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding Shares, and the
Exercise Price shall be proportionately increased.

 

6.1.3
Replacement of Securities upon Reorganization, Etc. In case of any reclassification or reorganization of the outstanding
Shares other than a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the par value of such Shares, or in the case
of any share reconstruction or amalgamation or consolidation or merger of the Company with or into another corporation (other than a
consolidation or share reconstruction or amalgamation or merger in which the Company is the continuing company and that does not
result in any reclassification or reorganization of the outstanding Shares), or in the case of any sale or conveyance to another corporation
or entity of the property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved,
the Holder of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant)
to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event, the kind
and amount of shares or other securities or property (including cash) receivable upon such reclassification, reorganization,
share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such sale or transfer, by a Holder of the
number of Shares of the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification
also results in a change in Shares covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant to Sections 6.1.1,
6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications, reorganizations,
share reconstructions or amalgamations, or consolidations, sales or other transfers.

 

6.1.4
Changes in Form of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to
this Section 6.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are
stated in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase
Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the Commencement
Date or the computation thereof.

 

6.2
Substitute Purchase Warrant. In case of any consolidation of the Company with, or share reconstruction
or amalgamation or merger of the Company with or into, another corporation (other than a consolidation or share reconstruction or amalgamation
or merger which does not result in any reclassification or change of the outstanding Shares), the corporation formed by such consolidation
or share reconstruction or amalgamation shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder
of each Purchase Warrant then outstanding or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase
Warrant) to receive, upon exercise of such Purchase Warrant, the kind and amount of shares and other securities and property receivable
upon such consolidation or share reconstruction or amalgamation, by a holder of the number of Shares of the Company for which such Purchase
Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation or merger, sale or transfer.
Such supplemental Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this Section
6. The above provision of this Section shall similarly apply to successive consolidations or share reconstructions or amalgamations or
mergers.

 

    5

     

    

 

6.3
Elimination of Fractional Interests. The Company shall not be required to issue certificates representing fractions of Shares
upon the exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it
being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may
be, to the nearest whole number of Shares or other securities, properties or rights.

 

7.
Reservation. The Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of
issuance upon exercise of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be issuable
upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of the Exercise
Price therefor, in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall be duly and validly
issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder.

 

8.
Certain Notice Requirements.

 

8.1
Holder’s Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holder the right to vote or
consent or to receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as
a shareholder of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the
events described in Section 8.2 shall occur, then, in one or more of said events, the Company shall deliver to each Holder a copy of
each notice relating to such events given to the other shareholders of the Company at the same time and in the same manner that such
notice is given to the shareholders.

 

8.2
Events Requiring Notice. The Company shall be required to give the notice described in this Section 8 upon one or more of the
following events: (i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a
dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings,
as indicated by the accounting treatment of such dividend or distribution on the books of the Company, or (ii) the Company shall offer
to all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or exchangeable
for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor.

 

8.3
Notice of Change in Exercise Price. The Company shall, within 3 Busines Days after an event requiring a
change in the Exercise Price pursuant to Section 6 hereof, send notice to the Holders of such event and change (“Price Notice”).
The Price Notice shall describe the event causing the change and the method of calculating same.

 

8.4
Transmittal of Notices. All notices, requests, consents and other communications under this
Purchase Warrant shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service
to following addresses or to such other address as the Holder or the Company may designate by notice to the other party and shall be deemed
given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail (with confirmation
of receipt from the intended recipient by return e-mail or other written acknowledgment) at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Business Day after the time of transmission, if such notice or communication
is delivered via e-mail (with confirmation of receipt from the intended recipient by return email or other written acknowledgment) at
the e-mail address set forth in this Section on a day that is not a Business Day or later than 5:30 p.m. (New York City time) on any Business
Day, (iii) the second Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or
(iv) upon actual receipt by the party to whom such notice is required to be given:

 

If
to the Holder:

 

Aegis
Capital Corp.,

810
Seventh Avenue, 18th Floor,

New
York, NY 10019,

Attention:
Global Equity Markets

E-mail: [●]

 

    6

     

    

 

with
a copy (which shall not constitute notice) to:

 

Anthony
W. Basch, Esq.

Kaufman
& Canoles, P.C.

1021
E. Cary Street, Suite 1400

Two
James Center

Richmond,
VA 23219

E-mail: awbasch@kaufcan.com

 

If
to the Company:

 

Maris-Tech
Ltd.

3 Golda Meir Street

Ness
Ziona, Israel 7403648

Attention:
Israel Bar, Chief Executive Officer

E-mail: israel@maris.co.il

 

with
a copy (which shall not constitute notice) to:

 

Oded
Har-Even, Esq.

Angela
Gomes, Esq.

Sullivan
& Worcester LLP

1633
Broadway

New
York, NY 10019

E-mail: ohareven@sullivanlaw.com; agomes @sullivanlaw.com

 

9.
Miscellaneous.

 

9.1
Amendments. The Company and Holder may from time to time supplement or amend this
Purchase Warrant without the approval of any of the Holders in order to cure any ambiguity, to correct or supplement any provision contained
herein that may be defective or inconsistent with any other provisions herein, or to make any other provisions in regard to matters or
questions arising hereunder that the Company and Holder may deem necessary or desirable and that the Company and Holder deem shall not
adversely affect the interest of the Holders. All other modifications or amendments shall require the written consent of and be signed
by (i) the Company and (ii) the Holder(s) of Purchase Warrants then-exercisable for at least a majority of the Shares then-exercisable
pursuant to all then-outstanding Purchase Warrants.

 

9.2
Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or
affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant.

 

9.3.
Entire Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection
with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes
all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

9.4
Binding Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company
and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions
herein contained.

 

9.5
Governing Law; Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced
in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby
agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant shall be brought
and enforced in the courts located in the City of New York, County of New York, and State of New York, and irrevocably submits to such
jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that
such courts represent an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting a copy
thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section
8 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or
claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from the other
party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection
with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders
and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

 

    7

     

    

 

9.6
Non-Waiver. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall
not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any
provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No
waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set
forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver
of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach,
non-compliance or non-fulfillment.

 

9.7
Exchange Agreement. As a condition of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that,
at any time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and Holder enter into an agreement (“Exchange
Agreement”) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash
or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.

 

[Signature
Page Follows]

 

    8

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly authorized officer as of the date first written
above.

 

Maris-Tech
Ltd.

 

	By:	 	 
		Name:	Israel Bar	 
		Title:	Chief Executive Officer	 

 

    9

     

    

 

[Form
to be used to exercise Purchase Warrant]

 

Date:
__________, 20___

 

The
undersigned hereby elects irrevocably to exercise the Purchase Warrant for ______ ordinary shares, no par value per share (the “Shares”),
of Maris-Tech Ltd., an Israeli company (the “Company”), and hereby makes payment of $____ (at the rate of $____
per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as to which this Purchase Warrant is exercised
in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which
this Purchase Warrant has not been exercised.

 

or

 

The
undersigned hereby elects irrevocably to convert its right to purchase ___ Shares of the Company under the Purchase Warrant for ______
Shares, as determined in accordance with the following formula:

 

	 	X	=	Y(A-B)	 
	A	 
	Where,	 	 	 
	 	X	=	The number
    of Shares to be issued to Holder;
	 	Y	=	The number of Shares for which the Purchase
    Warrant is being exercised;
	 	A	=	The fair market value of one Share which
    is equal to $_____; and
	 	B	=	The Exercise Price which is equal to $______
    per share
	 	 	 	 	 	 	 

The
undersigned agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement
with respect to the calculation shall be resolved by the Company in its sole discretion.

 

Please
issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a
new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been converted.

 

	 	Signature 	 	 

 

	 	Signature Guaranteed	 	 

 

INSTRUCTIONS
FOR REGISTRATION OF SECURITIES

 

	Name:	 	 
	 	(Print
in Block Letters)	 

 

	Address: 	 	 
	 	 	 

 

NOTICE:
The signature to this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange.

 

    10

     

    

 

[Form
to be used to assign Purchase Warrant]

 

ASSIGNMENT

 

(To
be executed by the registered Holder to effect a transfer of the within Purchase Warrant):

 

FOR
VALUE RECEIVED, __________________ does hereby sell, assign and transfer unto the right to purchase ordinary shares, no par value per
share, of Maris-Tech Ltd., an Israeli company (the “Company”), evidenced by the Purchase Warrant and does hereby
authorize the Company to transfer such right on the books of the Company.

 

Dated:
__________, 20__

 

	Signature 	 	 

 

	Signature Guaranteed	 	 

 

NOTICE:
The signature to this form must correspond with the name as written upon the face of the within Purchase Warrant without alteration or
enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm
having membership on a registered national securities exchange.

 

 

11Exhibit 10.1

 

MARIS TECH LTD.

LETTER OF INDEMNIFICATION 

 

Dated ________

 

Dear ________,

 

This letter agreement (“Letter”)
is provided to you in recognition that it is in the best interests of Maris Tech Ltd. (“Company”) to provide hereunder
for your indemnification to the fullest extent permitted by law.

 

		1.	The Company hereby undertakes to indemnify you to the maximum extent permitted by applicable law in respect
of the following:

 

		1.1	any financial obligation imposed on you in favor of another person by a court judgment, including a settlement
or an arbitrator’s award approved by court, in respect of any act or omission (“action”) taken or made by you in your
capacity as a director or officer of the Company, including without limitation, but subject to § ‎2
below, any amount reasonably incurred or suffered by you in connection with such an action; and

 

		1.2	all reasonable litigation expenses, including attorneys’ fees, expended by you or charged to you by a
court, in a proceeding instituted against you by the Company or on its behalf or by another person, or in any criminal proceedings in
which you are acquitted, or in any criminal proceedings of a crime which does not require proof of mens rea (criminal thought)
in which you are convicted, all in respect of actions taken by you in your capacity as a director or officer of the Company.

 

		2.	Notwithstanding § ‎1 above, the
Company will not indemnify you for any amount you may be obligated to pay in respect of:

 

		2.1	a breach of your duty of loyalty, except, to the extent permitted by law, for a breach of your duty of
loyalty to the Company or a Subsidiary while acting in good faith and having reasonable cause to assume that such act would not prejudice
the interests of the Company or Subsidiary, as applicable;

 

		2.2	a willful breach of your duty of care or reckless disregard for the circumstances or to the consequences
of a breach of your duty of care;

 

		2.3	an action taken or not taken with the intent of unlawfully realizing personal gain;

 

		2.4	a fine or penalty imposed upon you;

 

		2.5	With respect to proceedings or claims initiated or brought voluntarily by you other than by way of defense
or by way of third-party notice to the Company in connection with claims brought against you, except in specific cases in which the Board
of Directors of the Company has approved the initiation or bringing of such suit, which approval shall not be unreasonably withheld;

 

		3.	To the fullest extent permitted by law, the Company will make available all amounts needed in accordance
with § ‎1 above on the date on which such amounts are first payable
by you (“Time of Indebtedness”), and with respect to items referred to in § ‎1.2
above, even prior to a court decision, provided however, that advances given to cover legal expenses in criminal proceedings will be repaid
by you to the Company if you are found guilty of a crime which requires mens rea. Other advances will be repaid by you to the Company
if it is determined that you are not entitled to such indemnification as authorized hereby.

 

As part of the aforementioned undertaking,
the Company will make available to you any security or guarantee that you may be required to post in accordance with an interim decision
given by a court or an arbitrator, including for the purpose of substituting liens imposed on your assets. 

 

    - 1 -

     

    

 

		4.	The Company will indemnify you even if at the relevant Time of Indebtedness, you are no longer a director
or officer of the Company or of a Subsidiary, as applicable, provided, that the obligations are in respect of actions taken by you while
you were a director or officer, and in such capacity. 

 

		5.	The Company’s undertaking to indemnify you for the expenses mentioned in § ‎1.2
above (pursuant and subject to § ‎3 above and insofar as indemnification
with respect thereto is not restricted by law or by the provisions of § ‎2
above) and for the matters mentioned in Section ‎1.1 above shall apply
only insofar as such expenses or matters result from your actions in the following matters or in connection therewith:

 

		5.1	The offering of securities by the Company or by a shareholder to the public or to private investors or
the offer by the Company to purchase securities from the public or from private investors or other holders pursuant to a prospectus, agreement,
notice, report, tender or other proceeding;

 

		5.2	Occurrences in connection with investments the Company or Subsidiaries make in other corporations whether
before or after the investment is made, entering into the transaction, the execution, development and monitoring thereof, including actions
taken by you in the name of the Company or a Subsidiary as a director, officer or board observer of the corporation which is the subject
of the transaction and the like;

 

		5.3	The sale, purchase and holding of negotiable securities or other investments for or in the name of the
Company or a Subsidiary;

 

		5.4	Actions in connection with the merger of the Company or a Subsidiary with or into another entity;

 

		5.5	Actions in connection with the sale of the operations or business, or part thereof, of the Company or
a Subsidiary;

 

		5.6	Without derogating from the generality of the above, actions in connection with the purchase or sale of
companies, legal entities or assets, and the division or consolidation thereof;

 

		5.7	Actions taken in connection with labor relations or employment matters in the Company or the Subsidiaries
and trade relations of the Company or the Subsidiaries, including with employees, independent contractors, customers, suppliers and various
service providers;

 

		5.8	Actions in connection with the development or testing of products developed by the Company or the Subsidiaries,
or in connection with the distribution, sale, license or use of such products, including without limitation in connection with professional
liability and product liability claims;

 

		5.9	Actions taken in connection with the intellectual property of the Company or the Subsidiaries, and its
protection, including the registration or assertion of rights to intellectual property and the defense of claims related to intellectual
property, including any assertion that the Company’s products infringe on the intellectual property rights or constitute a misappropriation
of any third party’s trade secrets;

 

		5.10	Actions taken pursuant to or in accordance with the policies and procedures of the Company or the Subsidiaries
(including tax policies and procedures), whether such policies and procedures are published or not;

 

    - 2 -

     

    

 

		5.11	Approval of corporate actions, in good faith, including the approval of the acts of the Company’s
management, their guidance and their supervision.

 

		5.12	Claims of failure to exercise business judgment and a reasonable level of proficiency, expertise and care
in regard of the Company’s business;

 

		5.13	Violations of laws requiring the Company to obtain regulatory and governmental licenses, permits and authorizations
in any jurisdiction; and

 

		5.14	Claims in connection with publishing or providing any information, including any filings with governmental
authorities, on behalf of the Company in the circumstances required under applicable laws.

 

		6.	The total aggregate amount of indemnification for which the Company undertakes to indemnify you hereunder,
for all of the matters and circumstances described herein (cumulative), shall not exceed an amount equal to US$ 5,000,000 in the aggregate,
calculated with respect to each director and officer of the Company.

 

		7.	The Company will not indemnify you for any liability with respect to which you have received payment by
virtue of an insurance policy or another indemnification agreement other than for amounts which are in excess of the amounts actually
paid to you pursuant to any such insurance policy or other indemnity agreement (including deductible amounts not covered by insurance
policies), within the limits set forth in § ‎6 above.

 

		8.	Subject to the provisions of §§ ‎6
and ‎7 above, the indemnification hereunder will, in each case, cover
all sums of money (100%) that you will be obligated to pay, in those circumstances for which indemnification is permitted under the law.

 

		9.	The Company will be entitled to any amount actually received from a third party (including under an insurance)
in connection with liabilities indemnified hereunder, to be paid by you to the Company within fifteen (15) days following the receipt
of the said amount.

 

		10.	In all indemnifiable circumstances, indemnification will be subject to the following:

 

		10.1	You shall promptly notify the Company in writing of any legal proceedings initiated against you and of
all possible or threatened legal proceedings without delay following your first becoming aware thereof, and you shall deliver to the Company,
or to such person as it shall advise you, without delay all documents you receive or possess in connection with these proceedings or possible
or threatened proceedings. Notice to the Company shall be directed to the Chief Executive Officer of the Company at the address shown
in the signature page of this Letter (or such other address as the Company shall designate to you).

 

		10.2	Similarly, you must notify the Company in writing (addressed as described in § ‎10.1
above) on an ongoing and current basis concerning all events that you suspect may possibly give rise to the initiation of legal proceedings
against you.

 

		10.3	Other than with respect to proceedings that have been initiated against you by the Company or in its name,
the Company shall be entitled to undertake the conduct of your defense in respect of such legal proceedings and/or to hand over the conduct
thereof to any attorney which the Company may choose for that purpose, except to an attorney that you reasonably deem to be unacceptable.
The Company or the attorney as aforesaid shall be entitled, within the context of the conduct as aforesaid, to conclude such proceedings,
all as it shall see fit, including by way of settlement. At the request of the Company, you shall execute all documents required to enable
the Company and/or its attorney as aforesaid to conduct your defense in your name, and to represent you in all matters connected therewith,
in accordance with the aforesaid. For the avoidance of doubt, in the case of criminal proceedings the Company and/or the attorneys as
aforesaid will not have the right to plead guilty in your name or to agree to a plea-bargain in your name without your consent. Furthermore,
in a civil proceeding (whether before a court or as a part of a compromise arrangement), the Company and/or its attorneys will not have
the right to admit to any occurrences that are not indemnifiable pursuant to this Letter and/or pursuant to law, without your consent.
However, the aforesaid will not prevent the Company and/or its attorneys as aforesaid, with the approval of the Company, to come to a
financial arrangement with a plaintiff in a civil proceeding without your consent so long as such arrangement will not be an admittance
of an occurrence not fully indemnifiable pursuant to this Letter or pursuant to law and further provided that any such settlement or arrangement
does not impose on you any liability or limitation.

 

    - 3 -

     

    

 

		10.4	You will fully cooperate with the Company or any attorney as aforesaid in every reasonable way as may
be required of you within the context of their conduct of such legal proceedings, including but not limited to the execution of power(s)
of attorney and other documents, provided that the Company shall cover all costs incidental thereto such that you will not be required
to pay the same or to finance the same yourself.

 

		10.5	If, in accordance with § ‎10.3
above, the Company has taken upon itself the conduct of your defense, you shall have the right to employ counsel in any such action, suit
or proceeding, but the fees and expenses of such counsel, incurred after the assumption by the Company of the defense thereof, shall be
at your expense unless: (i) the employment of counsel by you has been authorized by the Company; or (ii) you and the Company shall have
reasonably concluded that there may be a conflict of interest between the Company and yourself in the conduct of the defense of such action,
in each of which cases the reasonable fees and expenses of counsel shall be at the expense of the Company.

 

		10.6	The Company will have no liability or obligation pursuant to this Letter to indemnify you for any amount
expended by you pursuant to any compromise or settlement agreement reached in any suit, demand or other proceeding as aforesaid without
the Company’s prior written consent to such compromise or settlement, which consent shall not be unreasonably withheld.

 

		11.	The Company hereby exempts you, to the fullest extent permitted by law, from any liability for damages
caused as a result of a breach of your duty of care to the Company, provided that in no event shall you be exempt with respect to any
actions listed in § ‎2 above.

 

		12.	If for the validation of any of the undertakings in this Letter any act, resolution, approval or other
procedure is required, the Company undertakes to make its best efforts to cause them to be done or adopted in a manner which will enable
the Company to fulfill all its undertakings as aforesaid.

 

		13.	For the avoidance of doubt, it is hereby clarified that nothing contained in this Letter derogates from
the Company’s right (but in no way obligation) to indemnify you post factum for any amounts which you may be obligated to pay as
set forth in § ‎1 above without the limitations set forth in
§§ ‎5 and ‎6
above. The Company may, in its sole discretion, following receipt of necessary corporate approvals, and subject to applicable law, indemnify
you retroactively for actions committed prior to the date of this Letter. Your rights of indemnification hereunder shall not be deemed
exclusive of any other rights you may have under the Company’s Articles of Association or applicable law or otherwise.

 

		14.	If any undertaking included in this Letter is held invalid or unenforceable, such invalidity or unenforceability
will not affect any of the other undertakings, which will remain in full force and effect. Furthermore, if such invalid or unenforceable
undertaking may be modified or amended so as to be valid and enforceable as a matter of law, such undertakings will be deemed to have
been modified or amended, and any competent court or arbitrator are hereby authorized to modify or amend such undertaking, so as to be
valid and enforceable to the maximum extent permitted by law.

 

    - 4 -

     

    

 

		15.	No supplement, modification or amendment of this Letter shall be binding unless executed in writing by
both of the parties hereto. No waiver of any of the provisions of this Letter shall be deemed or shall constitute a waiver of any other
provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. Any waiver shall be in writing.

 

		16.	This Letter and the agreements contained herein shall be governed by and construed and enforced in accordance
with the laws of the Israel.

 

		17.	This Letter of Indemnification cancels any preceding letter or other obligation of indemnification that
may have been issued to you.

 

This Letter is being issued to you pursuant to
the resolution adopted by the Board of Directors on ________.

 

Kindly sign in the space provided below to acknowledge
your agreement to the contents hereof, and return this Letter to the Company.

 

	 	Very truly yours,
	 	 
	 	MARIS TECH LTD.

 

 

- 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]